Published in final edited form as:

Nucleosides Nucleotides Nucleic Acids. 2009 May ; 28(5): 633–641. doi:10.1080/15257770903091920.

CARBOCYCLIC THYMIDINE ANALOGUES FOR USE AS POTENTIAL THERAPEUTIC AGENTS

Katherine L. Seley-Radtke and Naresh K. Sunkara

Department of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, Maryland, USA

Abstract

The discovery of azidothymidine's (AZT) activity against human immunodeficiency virus (HIV) provided strong rationale for the design of additional thymidine analogues. One drawback of many nucleoside analogues is the toxicity that often arises due to phosphorylation by cellular kinases. In order to overcome this problem, a number of truncated nucleosides lacking the 4'-hydroxymethyl group have been synthesized. In that regard, the synthesis and preliminary biological results for two truncated carbocyclic thymidine analogues are presented herein.

Keywords

Carbocyclic; nucleosides; pyrimidine; SAHase; neplanocin; aristeromycin

INTRODUCTION

Despite the significant biological activity exhibited by a variety of novel unnatural nucleosides, the pursuit of new analogues continues in an effort to decrease toxicity and improve efficacy in various biological systems.^[1] As a result, manipulation of the nucleoside scaffold both in the heterocyclic base and the sugar moiety has resulted in a number of potent antiviral and anticancer drugs.^[1–4] In that regard, a number of uridine and 5-substituted 2'-deoxyuridine nucleoside analogues (shown in Figure 1) such as 5-(E)-(bromovinyl)-2'-deoxyuridine (BVDU,^[5–7] **A**), 5-trifluoromethyl-2'-deoxyuridine (F3TDR, **B**), 5-iodo-2'-deoxyuridine (IUDR, **C**)^[8] and 5-bromo-2'-deoxyuridine (**D**), and 5-fluoro-2'-deoxyuridine (**E**) have exhibited antiviral and/or anticancer activity.^[7,9–11]

One particular structural modification that has proven fruitful is found in the carbocyclic nucleosides.^[12–16] Carbocyclic nucleosides possess a methylene group in place of the furanose oxygen in the sugar moiety of the nucleoside. This structural change imparts significant stability to the glycosidic bond, as well as increasing the overall lipophilicity of the nucleoside.^[17,18] A number of carbocyclic nucleosides have been synthesized and many have been found to possess potent biological activity, including the naturally occurring Neplanocin (NpcA) and Aristeromycin (Ari).^[9,17,19–21] To date most have been purine analogues, however due to the significant biological activity found among 2'-deoxy and 5-substituted 2'-deoxy pyrimidines the synthesis of the analogous carbocyclic nucleosides was also of interest and indeed, several have proven to be active.^[9,10,18,22,23]

In that regard, the carbocyclic analogue of thymidine (**F**) (Figure 1) exhibited activity against leukemia L1210 cell lines, as well as HSV-1 with a MIC₅₀ of 0.8 $\mu\text{g/mL}$.^[9,22,23] Furthermore, carbocyclic analogues of 5-substituted uridine (**G–J**) were found to be highly active *in vitro* against the herpes simplex virus, both type 1 and 2.^[9,17,20,22,23] The 5-iodo uridine analogue (**G**) proved to be the most active against HSV-1 with a MIC₅₀ in the range of 0.1–0.5 $\mu\text{g/mL}$.^[9,22,23] Other examples of biologically active carbocyclic pyrimidine analogues include cyclopentenyl cytosine (CPE-C, **K**, Figure 1),^[22,23] for which potent anti-West Nile activity was observed.^[24,25] Additionally, Chu et al. reported that L-fluorothymidine (**L**, Figure 1) exhibited moderate activity against HIV.^[24] The encouraging activity exhibited by the pyrimidine nucleoside analogues and in particular, thymidine analogues, provide an impetus to synthesize and explore the therapeutic activities of these analogues.

Despite their potent activity, one of the drawbacks of some carbocyclic nucleosides has been their susceptibility to phosphorylation by cellular kinases, resulting in significant cytotoxicity for the triphosphate analogues.^[26] In response to this, strategic removal of the 4'-hydroxymethyl group of aristeromycin (Ari) and neplanocin (NpcA) resulted in the development of new analogues (1'R,2'S,3'R)-9-(2',3'-dihydroxycyclopentan-1'-yl)adenine (DHCaA) and (1'R,2'S,3'R)-9-(2',3'-dihydroxycyclopent-4'-enyl)adenine (DHCEA) (Figure 1).^[27] Interestingly, both DHCaA and DHCEA retained potent antiviral activity but exhibited reduced cytotoxicity since neither DHCaA nor DHCEA serve as substrates for adenosine kinase or adenosine deaminase, both major causes of cytotoxicity associated with Ari and NpcA.^[28]

Related to this, we recently reported the synthesis of several carbocyclic uridine and cytidine nucleoside analogues possessing the truncated scaffold (Figure 2).^[30] The cytidine analogue **2** exhibited interesting activity against S-adenosylhomocysteine hydrolase (SAHase) and SAH nucleosidase. This finding was interesting because **2** is a pyrimidine analogue and these are adenosine-metabolizing enzymes.

As a logical extension to our previous studies of truncated pyrimidine nucleosides, synthesis of thymidine analogues **5** and **6** (Figure 3) was considered and the results are reported herein.

RESULTS AND DISCUSSION

Traditional Mitsunobu coupling of the thymine ring to an appropriate cyclopentyl intermediate was envisioned as a logical route to realize the targets **5** and **6**.^[30–32] Synthesis began with the reduction of the known protected carbocyclic ketone **7**, a common building block in carbocyclic nucleoside research that is obtained from commercially available D-ribose in five steps.^[33] Using literature methods,^[34] the carbonyl group on intermediate **7** was stereospecifically reduced to the down alcohol **8** using Luche^[35] conditions with cerium (III) chloride heptahydrate as shown in Scheme 1. Compound **8** was then coupled to N³-Bz-thymine **9** using Mitsunobu conditions to afford **10** in 60% yield.^[30–32]

Next, the benzoyl-protecting group on **10** was deblocked (Scheme 1) by treatment with a 1% NaOH solution in MeOH to afford intermediate **11** in 75% yield.^[30,32] The isopropylidene group of analogue **11** was then removed using a mixture of TFA and H₂O (2:1) in THF to result in the first thymidine target **5**.^[30]

In order to obtain the saturated target **6**, protected intermediate **11** was reduced using 10% Pd/C and H₂ at 25 psi to give **12** in 90% yield.^[28,30] The isopropylidene group of **12** was then deprotected under standard conditions to quantitatively provide **6**.^[28,36]

Carbocyclic thymidine analogues **5** and **6** were then screened against the National Cancer Institute's 60 cell lines, as well as subjected to broad screen testing against a number of viruses by Southern Research Institute. Unfortunately neither **5** nor **6** showed any meaningful activity. In addition, because of the unexpected inhibitory activity exhibited by our previous truncated pyrimidine analogues against SAHase, **5** and **6** were also assayed against this enzyme.^[30] Not surprisingly however, since, as previously mentioned, SAHase is almost exclusively an adenosine-metabolizing enzyme, neither of these compounds proved to be an inhibitor. Current efforts are underway to investigate additional modifications, and the results of those studies will be reported as they become available.

EXPERIMENTAL

General Experimental Methods

All chemicals were obtained from commercial sources and used without further purification unless otherwise noted. Anhydrous DMF, MeOH, DMSO, and toluene were purchased from Fisher Scientific. Anhydrous THF, acetone, CH₂Cl₂, CH₃CN, and ether were obtained using a solvent purification system (mBraun Labmaster 130). NMR solvents were purchased from Cambridge Isotope Laboratories (Andover, MA, USA). All ¹H and ¹³C NMR spectra were obtained on a JEOL ECX 400 MHz NMR, operated at 400 and 100 MHz respectively, and referenced to internal tetramethylsilane (TMS) at 0.0 ppm. The spin multiplicities are indicated by the symbols s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet), and b (broad). Reactions were monitored by thin-layer chromatography (TLC) using 0.25 mm Whatman Diamond silica gel 60-F254 precoated plates. Column chromatography was performed using silica gel (63–200 μm) from Dynamic Adsorptions Inc. (Norcross, GA, USA), and eluted with the indicated solvent system. Yields refer to chromatographically and spectroscopically (¹H and ¹³C NMR) homogeneous materials. Mass spectra were recorded at the Johns Hopkins Mass Spectrometry Facility. Elemental analyses were recorded at Atlantic Microlabs, Inc. (Norcross, GA, USA). All chemicals were obtained from commercial sources and used without further purification unless otherwise noted.

Preparation of 1-(2'-3'-O-Isopropylidenedioxycyclopent-1-yl)-thymine (11)—To **8**^[35] (0.75 g, 4.8 mmol), *N*³-benzoylthymine (2.2 g, 9.61 mmol) and PPh₃ (3.14 g, 12 mmol) in anhydrous CH₃CN (500 mL) at 0°C was added dropwise diisopropylazodicarboxylate (2.42 g, 12 mmol, 2.36 mL). After stirring at room temperature for 15 hours, the mixture was concentrated and purified by column chromatography eluting with EtOAc:hexane (3:1) to afford 1.71 g of **10** as a white solid (66%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.32 (3 H, s); 1.38 (3 H, s); 1.84 (3 H, s); 4.68 (1 H, m); 5.31 (1 H, dd); 5.37 (1 H, dd); 5.79 (1 H, m); 6.21 (1 H, m); 7.22 (1 H, s); 7.51 (2 H, m); 7.72 (1 H, m); 7.92 (2 H, m). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 21.1, 22.4, 24.7, 26.4, 60.2, 68.8, 83.3, 84.7, 110.1, 111.7, 129.2, 129.4, 130.3, 131.6, 135.2, 138.7, 149.9, 163.5, 169.3, 171.5.

NaOH (10 mL, 1% in MeOH) was added to **10** (1.7 g, 4.7 mmol) and the mixture allowed to stir at room temperature for 12 hours, then neutralized with 1M HCl. The mixture was evaporated and the resulting residue dissolved in EtOAc (50 mL), washed with H₂O (25 mL), dried (anhydrous MgSO₄), and the solvent evaporated under vacuum. The residue was purified by column chromatography eluting with EtOAc:hexane (4:1) to afford 0.95 g of **11** as a white solid (79%). ¹H NMR (400 MHz, CD₃OD) δ 1.29 (3 H, s); 1.37 (3 H, s); 1.82 (3 H, s); 4.61 (1 H, d); 5.38 (1 H, m); 5.41 (1 H, m); 5.79 (1 H, m); 6.21 (1 H, m); 7.11 (1 H, s). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 24.6, 26.4, 60.23, 68.24, 83.47, 84.7, 110.1, 111.6, 129.4, 138.2, 151.4, 165.1, 171.5. HRMS: Calcd for C₁₃H₁₆N₂O₄ (M+H)⁺, 265.1111; Found, 265.1429.

Preparation of 1-(2',3'-Dihydroxycyclopent-2-enyl)-thymine (5)—To a mixture of trifluoroacetic acid and H₂O (2:1, 50 mL) was added **11** (0.21 g, 0.75 mmol) and the mixture stirred for 2 hours. The solvent was removed under vacuum and the residue purified by column chromatography eluting with EtOAc:MeOH, (10:1) to afford 0.13 g of **5** as a white solid (78%). ¹H NMR (400 MHz, CD₃OD) δ 1.85 (3H, s); 4.11 (1H, m); 4.04 (1H, t); 4.57 (1H, m); 6.17 (1H, m); 7.19 (1H, m). ¹³C NMR (75 MHz, CD₃OD) 10.9, 66.3, 72.9, 76.4, 110.4, 132.8, 136.3, 137.9, 151.9, 165.2. Anal. Calcd for C₁₀H₁₂N₂O₄ (0.10 H₂O): C, 53.30, H, 5.40, N, 12.10. Found: C, 53.32, H, 5.50, N, 12.04.

Preparation of 1-(2',3'-O-Isopropylidenedioxycyclopent-1-yl)-thymine (12)—To a solution of **11** (0.500 g, 1.89 mmol) in MeOH (10 mL) Pd/C (10%, 0.040 g) was added and the mixture subjected to hydrogenation conditions at a pressure of 0.17 MPa for 20 minutes. The mixture was filtered and the filtrate concentrated under vacuum to afford 0.498 g of **12** as a white solid (quantitative). ¹H NMR (400 MHz, CD₃OD) δ 1.26 (3 H, s); 1.37 (3 H, s); 1.81 (3 H, s); 1.88–1.98 (2 H, m); 4.63 (1 H, d); 5.35 (1 H, m); 5.41 (1 H, m); 5.79 (1 H, m); 6.21 (1 H, m); 7.11 (1 H, s). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 24.6, 26.4, 60.3, 68.3, 83.5, 84.7, 110.1, 111.6, 129.1, 138.2, 151.3, 165.1, 171.5. HRMS: Calcd for C₁₃H₁₈N₂O₄ (M+H)⁺, 267.1267; Found, 267.1340.

Preparation of 1-(2',3'-Dihydroxycyclopentyl)-thymine (6)—Compound **12** (0.200 g, 0.75 mmol) was dissolved in a mixture of trifluoroacetic acid and water (2:1, 50 mL) and stirred for 2 hours. The solvent was removed under vacuum and the residue purified by column chromatography eluting with EtOAc: MeOH (10:1) to afford 0.16 g of **6** as a white solid (quantitative). ¹H NMR (400 MHz, DMSO) δ 1.42–1.52 (2 H, m); 1.72–1.78 (3 H, m); 1.89–1.97 (2 H, m); 3.81–3.87 (1 H, m); 3.96–4.18 (1 H, m); 4.52–4.54 (1 H, d); 4.56–4.62 (1 H, m); 4.78–4.82 (1 H, d); 7.53–7.56 (1 H, d); 11.2 (1 H, s). ¹³C NMR (75 MHz, DMSO) 15.5, 19.9, 26.2, 59.8, 77.2, 85.9, 110.9, 137.5, 150.9, 163.8. Anal. Calcd. for C₁₀H₁₄N₂O₄ (0.10 H₂O); C, 52.62, H, 6.22, N, 11.70. Found: C, 52.65, H, 6.34, N, 11.83.

Acknowledgments

This work was supported by the National Institutes of Health (RO1 CA97634, KSR). The authors also want to thank Dr. Sunny Zhou of Northeastern University for performing the SAHase assays.

References

1. De Clercq E. Antivirals and Antiviral strategies. *Nature Reviews*. 2004; 2:704–720.
2. De Clercq E. New approaches toward anti-HIV chemotherapy. *J Med Chem*. 2005; 48:1297–1313. [PubMed: 15743172]
3. De Clercq E. Antiviral activity spectrum and target of action of different classes of Nucleoside analogues. *Nucleosides Nucleotides*. 1994; 13:1271–1295.
4. Robins, RK.; Revankar, GR. *Advances in Anti Viral Drug Design*. JAI Press; Greenwich: 1993.
5. Griengl H, Hayden W, Penn G, De Clercq E, Rosenwirth B. Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity. *J Med Chem*. 1988; 31:1831–1839. [PubMed: 2842506]
6. Jones AS, Sayers JR, Walker RT, De Clercq E. Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2'-deoxycytidine-related compounds. *J Med Chem*. 1988; 31:268–271. [PubMed: 2826786]
7. Russ P, Schelling P, Scapozza L, Folkers G, Clercq ED, Marquez VE. Synthesis and biological evaluation of 5-substituted derivatives of the potent antih herpes agent (north)-methanocarbothymine. *J Med Chem*. 2003; 46:5045–5054. [PubMed: 14584954]

8. Balzarini J, Baumgartner H, Bodenteich M, De Clercq E, Griengl H. Synthesis and Antiviral Activity of the Enantiomeric Forms of Carba-5-iodo-2'-deoxyuridine and Carba-(*E*)-5-(2-bromovinyl)-2'-deoxyuridine. *J Med Chem.* 1989; 32:1861–1865. [PubMed: 2547072]
9. Shealy YF, O'Dell CA, Shannon WM, Arnett G. Carbocyclic analogues of 5-substituted uracil nucleosides: synthesis and antiviral activity. *J Med Chem.* 1983; 26:156–161. [PubMed: 6298423]
10. Prusoff WH, Chen MS, Fischer PH, Lin TS, Shiau GT, Schinazi RF, Walker J. Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2'-deoxyuridine; 5-iodo-2'-deoxycytidine; 5-iodo-5'-amino-2',5'-dideoxyuridine. *Pharmacol Ther.* 1979; 7:1–34. [PubMed: 392550]
11. Prusoff WH, Ward DC, Lin TS, Chen MS, Shaiu GT, Chai C, Lentz E, Capizzi R, Idriss J, et al. Recent studies on the antiviral and biochemical properties of 5-halo-5'-amino-deoxyribonucleosides. *Ann N Y Acad Sci.* 1977; 284:335–341. [PubMed: 212979]
12. Agrofoglio L, Suhas E, Farese A, Condom R, Challand SR, Earl RA, Guedj R. Synthesis of carbocyclic nucleosides. *Tetrahedron.* 1994; 50:10611–70.
13. Jenny TF, Horlacher J, Previsani N, Benner SA. Carbocyclic Analogs of Nucleosides. *Helv Chim Acta.* 1992; 75:1944–1954.
14. Ogawa A, Shuto S, Tanaka M, Sasaki T, Mori S, Shigeta S, Matsuda A. Nucleosides and Nucleotides. 186. Synthesis and Biological Activities of Pyrimidine Carbocyclic Nucleosides with a Hydroxylamino Group Instead of a Hydroxymethyl Group at the 4'-Position of the Sugar Moiety. *Chem Pharm Bull.* 1999; 47:1000–1005. [PubMed: 10434401]
15. Marquez VE, Lim MI. Carbocyclic nucleosides. *Med Res Rev.* 1986; 6:1–40. [PubMed: 3512934]
16. Zhu XF. The Latest Progress in the Synthesis of Carbocyclic Nucleosides. *Nucleosides Nucleotides Nucleic Acids.* 2000; 19:651–690. [PubMed: 10843500]
17. Marquez, VE. Carbocyclic nucleosides. In: De Clercq, E., editor. *Advances in Antiviral Drug Design.* Vol. 2. JAI Press; Greenwich, CT: 1996. p. 89-146.
18. Marquez VE, Lim MI, Treanor SP, Plowman J, Priest MA, Markovac A, Khan MS, Kaskar B, Driscoll JS. Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. *J Med Chem.* 1988; 31:1687–94. [PubMed: 3411597]
19. Beres J, Sagi G, Tomoskozi I, Gruber L, Baitz-Gacs E, Otvos L, De Clercq E. Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1*R*,5*S*)- and (–)-(1*S*,5*R*)-2-oxabicyclo[3.3.0]oct-6-en-3-one. *J Med Chem.* 1990; 33:1353–1360. [PubMed: 2158560]
20. Smee DF, Wandersee MK, Bailey KW, Wong MH, Chu CK, Gadthula S, Sidwell RW. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. *Antiviral Res.* 2007; 73:69–77. [PubMed: 16712967]
21. De Clercq E. Carbocyclic adenosine analogues as *S*-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances. *Nucleosides Nucleotides.* 1998; 17:625–634. [PubMed: 9708366]
22. De Clercq E, Bernaerts R, Shealy YF, Montgomery JA. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. *Biochem Pharmacol.* 1990; 39:319–325. [PubMed: 1689159]
23. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytotoxic activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. *Biochem Pharmacol.* 1991; 41:1821–1829. [PubMed: 1710119]
24. Song GY, Paul V, Choo H, Morrey J, Sidwell RW, Schinazi RF, Chu CK. Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West Nile virus. *J Med Chem.* 2001; 44:3985–3993. [PubMed: 11689085]
25. Wang J, Jin Y, Rapp KL, Schinazi RF, Chu CK. D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance. *J Med Chem.* 2007; 50:1828–39. [PubMed: 17373782]
26. Glazer RI, Knode MC, Neplanocin A. A Cyclopentyl Analog of Adenosine with Specificity for Inhibiting RNA Methylation. *J Biol Chem.* 1984; 259:12964–12969. [PubMed: 6333423]
27. Hasobe M, Liang H, Ault-Riche DB, Borcharding DR, Wolfe MS, Borchardt RT. (1'*R*, 2'*S*, 3'*R*)-9-(2', 3'-Dihydroxycyclopentan-1'-yl)-adenine and -3-Deaza-adenine: Analogues of Aris-

- teromycin Which Exhibit Potent Antiviral Activity with Reduced Toxicity. *Antivir Chem Chemother.* 1993; 4:245–248.
28. Hasobe M, McKee JG, Borcharding DR, Borchardt RT. 9-(*trans*-2', *trans*-3'-Dihydroxycyclopent-4'-enyl)-Adenine and -3-deazaadenine: analogs of neplanocin A Which retain potent antiviral activity but exhibit reduced cytotoxicity. *Antimicrob Agents Chemother.* 1987; 31:1849–1851. [PubMed: 2449123]
29. Hasobe M, McKee JG, Borcharding DR, Keller BT, Borchardt RT. Effects of 9-(*trans*-2', *trans*-3'-Dihydroxycyclopent-4'-enyl)-Adenine and -3-Deazaadenine on the Metabolism of *S*-Adenosylhomocysteine in Mouse L929 Cells. *Mol Pharmacol.* 1988; 33:713–720. [PubMed: 2454388]
30. Mosley SL, Bakke BA, Sadler JM, Sunkara NK, Dorgan KM, Zhou ZS, Seley-Radtke KL. Carbocyclic pyrimidine nucleosides as inhibitors of *S*-adenosylhomocysteine hydrolase. *Bioorg Med Chem.* 2006; 14:7967–7971. [PubMed: 16904326]
31. Mitsunobu O. The use of diethyl azodicarboxylate and triphenylphosphine in Synthesis and Transformation of natural products. *Synthesis.* 1981:1–28.
32. Mitsunobu O, Takizawa S, Morimoto H. Benzoylation of uridine derivatives. *J Am Chem Soc.* 1976; 98:7858–9. [PubMed: 993503]
33. Yang M, Ye W, Schneller SW. Preparation of carbocyclic *S*-adenosylazamethionine accompanied by a practical synthesis of (–)-aristeromycin. *J Org Chem.* 2004; 69:3993–3996. [PubMed: 15153042]
34. Seley KL, Schneller SW, Rattendi D, Lane S, Bacchi CJ. Synthesis and antitrypanosomal activities of a series of 7-deaza-5'-noraristeromycin derivatives with variations in the cyclopentyl ring substituents. *Antimicrob Agents Chemother.* 1997; 41:1658–1661. [PubMed: 9257736]
35. Luche J-L, Rodriguez-Hahn L, Crabbe P. Reduction of Natural enones in the presence of cerium trichloride. *J Chem Soc, Chem Commun.* 1978:601–602.
36. Bergstrom DE, Brattesani AJ, Ogawa MK, Reddy PA, Schweickert MJ, Balzarini J, De Clercq E. Antiviral activity of C-5 substituted tubercidin analogues. *J Med Chem.* 1984; 27:285–92. [PubMed: 6699874]

A; X=CH=CHBr, BVDU
B; X=I, IUDR
C; X=CF₃, trifluorothymidine
D; X=Br, 5-bromo-2'-deoxyuridine
E; X=F, 5-fluoro-2'-deoxyuridine

F; X=CH₃, carbocyclic thymidine
G; X=I, carbocyclic 5-iodo-2'-deoxyuridine
H; X=Br, carbocyclic 5-bromo-2'-deoxyuridine
I; X=NH₂, carbocyclic 5-amino-2'-deoxyuridine

J; X=OH, cyclopentenyl uridine (CPUC)
K; X=NH₂, cyclopentenyl cytosine (CPEC)

L; Carbocyclic-L-fluorothymidine

FIGURE 1.
Biologically significant pyrimidine nucleosides.

FIGURE 2.
Truncated purine carbocyclic nucleosides.

FIGURE 3.
Proposed truncated thymidine carbocyclic targets.

SCHEME 1.

Synthesis of **5** and **6**. Reagents and conditions: a, $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ NaBH_4 , MeOH, 0°C ; b, i) PPh_3 , DIAD, CH_3CN , 0°C to rt, 24 h; c, NaOH, MeOH, 12 h; d, TFA: H_2O (2:1), 1 h, rt; e, 10% Pd/C, H_2 , 25 psi, 25 min, rt.